Immuno-oncology
Defence Therapeutics Inc. has introduced the profitable testing of a second-generation anticancer vaccine, ARM-002, utilizing its lead anticancer molecule Accutox. When examined as a therapeutic vaccine in a melanoma most cancers mannequin, ARM-002 led to an 80% full response when mixed with an anti-PD-1 immune-checkpoint inhibitor.
BioWorld Science Most cancers Immuno-oncology Vaccine